SO-27 Efficacy and response rates of the RENCA Macrobead therapy (RMB): A novel approach to the treatment of metastatic colorectal cancer. phase II clinical trials [U.S. FDA BB-IND 10091]

Autor:	Lawrence S. Gazda, David J. Wolf, Angelica Nazarian, Barry Smith, Sudipta Sureshbabu, Nathaniel Berman, Thomas J. Fahey
Rok vydání:	2020
Předmět:	Oncology medicine.medical_specialty Colorectal cancer business.industry Internal medicine medicine Phases of clinical research Hematology RENCA Macrobead medicine.disease business
Zdroj:	Annals of Oncology. 31:S227
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2020.04.042
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::45e05cf9bcbc354b1aba4e6eb683fef5 https://doi.org/10.1016/j.annonc.2020.04.042 Zobrazit plný text záznamu